Outcomes of organ-preserving treatment of atypical hyperplasia and early stage endometrial cancer in reproductive age: A prospective and retrospective study
- 作者: Gadzhieva L.T.1,2, Pronin S.M.3, Pavlovich S.V.1,3, Kometova V.V.3, Ashrafyan L.A.3
-
隶属关系:
- Sechenov First Moscow State Medical University (Sechenov University)
- Moscow Multidisciplinary Clinical Center “Kommunarka”
- Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology
- 期: 卷 25, 编号 2 (2023)
- 页面: 177-182
- 栏目: ORIGINAL ARTICLE
- URL: https://journals.rcsi.science/2079-5831/article/view/134141
- DOI: https://doi.org/10.26442/20795696.2023.2.202219
- ID: 134141
如何引用文章
全文:
详细
Aim. To evaluate the effectiveness of the intrauterine levonorgestrel-releasing device (LNG-IUD) in the treatment of atypical hyperplasia and the use of LNG-IUD in combination with a gonadotropin-releasing hormone analog (3.6 mg goserelin depot) in the treatment of stage Ia highly differentiated endometrial adenocarcinoma in women wishing to preserve childbearing function, and to assess reproductive outcomes after treatment in these women.
Materials and methods. A prospective and retrospective series of cases included all patients treated with LNG-IUD or LNG-IUD combined with goserelin 3.2 for atypical hyperplasia or early endometrial cancer (EC) treated in the Department of Innovative Oncology and Gynecology of the Institute of Oncogynecology and Mammology of the Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology from January 2018 to March 2022. Response rates and the relationship of the response with clinical and pathological factors were calculated.
Results. Fifty-six patients diagnosed with atypical hyperplasia or stage Ia highly differentiated endometrial adenocarcinoma were treated with LNG-IUD and LNG-IUD combined with 3.2 mg of goserelin. Of the 56 patients who completed a 6-month course of hormonal treatment, 42 (82%) showed a complete response: 22 (91.7%) with atypical endometrial hyperplasia (AEH) and 20 (74.1%) with EC. In 4 (7.8%) patients, a partial response was reported: 2 (8.3%) with AEH and 2 (7.4%) with EC. No response was noted in 5 (9.8%) patients in the EC group only. Childbirth was reported in 13 (23.2%) women: 8 (29.6%) with AEH and 5 (17.2%) with EC. Two (3.6%) women were in the second trimester of pregnancy, and 17 (30.4%) women had an early pregnancy loss; 7 (25.9%) of them had AEH, and 10 (34.5%) had EC. The positive response rate was 90.2% at 6 months: 24 (100%) patients with atypical hyperplasia and 22 (81.5%) with EC. Patients with EC in combination with polycystic ovary syndrome and obesity and patients with the non-obese EC phenotype had a lower therapy efficacy.
Conclusion. LNG-IUD therapy for the conservative treatment of atypical hyperplasia and LNG-IUD therapy combined with goserelin 3.2 for early EC led to a morphological cure in most patients and can be considered for women planning pregnancy.
作者简介
Lyubov Gadzhieva
Sechenov First Moscow State Medical University (Sechenov University); Moscow Multidisciplinary Clinical Center “Kommunarka”
编辑信件的主要联系方式.
Email: amor-amor93@bk.ru
ORCID iD: 0009-0009-9106-6980
Graduate Student
俄罗斯联邦, Moscow; MoscowStanislav Pronin
Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology
Email: psm_doc@mail.ru
ORCID iD: 0009-0006-4422-7305
Cand. Sci. (Med.)
俄罗斯联邦, MoscowStanislav Pavlovich
Sechenov First Moscow State Medical University (Sechenov University); Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology
Email: st.pavlovich@mail.ru
ORCID iD: 0000-0002-1313-7079
Cand. Sci. (Med.)
俄罗斯联邦, Moscow; MoscowVlada Kometova
Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology
Email: vladakometova@gmail.com
ORCID iD: 0000-0001-9666-6875
Cand. Sci. (Med.)
俄罗斯联邦, MoscowLevon Ashrafyan
Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology
Email: levaa2004@yahoo.com
ORCID iD: 0000-0001-6396-4948
D. Sci. (Med.), Acad. RAS
俄罗斯联邦, Moscow参考
- Henley SJ, Ward EM, Scott S, et al. Annual report to the nation on the status of cancer, part I: national cancer statistics. Cancer. 2020;126(10):2225-49.
- Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. Cancer. 1985;56(2):403-12.
- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-9.
- Morice P, Leary A, Creutzberg C, et al. Endometrial cancer. Lancet. 2016;387(10023):1094-108.
- Pellerin GP, Finan MA. Endometrial cancer in women 45 years of age or younger: a clinicopathological analysis. Am J Obstet Gynecol. 2005;193(5):1640-4.
- Fujiwara H, Ogawa S, Motoyama M, et al. Frequency and characteristics of endometrial carcinoma and atypical hyper- plasia detected on routine infertility investigations in young women: a report of six cases. Hum Reprod. 2009;24(5):1045-50.
- Клинические рекомендации «Рак тела матки и саркомы матки». M., 2021 [Klinicheskiie rekomendatsii ”Rak tela matki i sarkomy matki”. Moscow, 2021 (in Russian)].
- Amant F, Moerman P, Neven P, et al. Endometrial cancer. Lancet. 2005;366(9484):491-505.
- Soliman PT, Oh JC, Schmeler KM, et al. Risk factors for young premenopausal women with endometrial cancer. Obstet Gynecol. 2005;105(3):575-80.
- Kaaks R, Lukanova A, Kurzer MS. Obesity, endogenous hormones, and endometrial cancer risk: a synthetic review. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1531-43.
- Soisson AP, Soper JT, Berchuck A, et al. Radical hysterectomy in obese women. Obstet Gynecol. 1992;80(6):940-3.
- Пронин С.М., Новикова О.В., Андреева Ю.Ю. Применение рилизинг-систем и агонистов гонадотропин-рилизинг-гормона в лечении атипической гиперплазии и начального рака эндометрия. Онкология. Журнал им. П.А. Герцена. 2013;1:40-3 [Pronin SM, Novikova OV, Andreeva YuYu. The use of releasing systems and gonadotropin-releasing hormone agonists in the treatment of atypical hyperplasia and early-stage endometrial cancer. PA Herzen Journal of Oncology. 2013;1:40-3 (in Russian)].
- Новикова О.В. Авасова Ч.А. Новикова Е.Г., и др. Новый вариант гормонального лечения атипической гиперплазии и начального рака эндометрия с сохранением фертильности. Онкогинекология. 2019;1(29):36-45 [Novikova OV, Avasova ChA, Novikova EG, et al. New variant of hormonal treatment for atypical endometrial hyperplasia and an early endometrial cancer with fertility preservation. Oncoginekologiia. 2019;1(29):36-45 (in Russian)].
- Minig L, Franchi D, Boveri S, et al. Progestin intrauterine device and GnRH analogue for uterus-sparing treatment of endometrial precancers and well-differentiated early endometrial carcinoma in young women. Ann Oncol. 2011;22(3):643-9.
- Бохман Я.В. Рак тела матки. Кишинев, 1972 [Bokhman IaV. Rak tela matki. Kishinev, 1972 (in Russian)].
- Ранняя онкологическая патология. Под ред. Б.Е. Петерсона, В.И. Чиссова. М., 1985 [Ranniaia onkologicheskaia patologiia. Pod red. BE Petersona, VI Chissova. Moscow, 1985 (in Russian)].
补充文件
